Showing results (11-20 of 40) with videos related to
Sort By:
Pageof 4
The Journal of Rheumatology|February 7, 1998
Clinically occult avascular necrosis of the hip in systemic lupus erythematosusC Aranow, S Zelicof, D Leslie, et al.AJNR. American Journal of Neuroradiology|February 23, 2019
Alterations in Blood-Brain Barrier Permeability in Patients with Systemic Lupus ErythematosusJ M Chi, M Mackay, A Hoang, et al.AJNR. American Journal of Neuroradiology|February 9, 2019
Dynamic Contrast-Enhanced MRI Reveals Unique Blood-Brain Barrier Permeability Characteristics in the Hippocampus in the Normal BrainJ Ivanidze, M Mackay, A Hoang, et al.Lupus|September 30, 2003
Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placeboV Strand, C Aranow, M H Cardiel, et al.International Reviews of Immunology|January 1, 1990
Pathogenic anti-DNA antibodies in SLE: idiotypic families and genetic originsE Paul, A Manheimer-Lory, A Livneh, et al.Lupus|March 4, 2016
Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of careI N Bruce, M Urowitz, R van Vollenhoven, et al.Biorxiv : the Preprint Server for Biology|November 28, 2024
IFN-associated B cell hyperactivity is highly enriched in SLE patients harboring Sm/RNP antibodiesH J van Dooren, Y Atisha-Fregoso, A L Dorjée, et al.Lupus|December 25, 2012
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLEM A Dooley, F Houssiau, C Aranow, et al.Lupus|September 4, 2001
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patientsP A McNeeley, G M Iverson, R A Furie, et al.The Journal of Rheumatology|March 15, 2001
Treatment of systemic lupus erythematosus with LJP 394R A Furie, J M Cash, M E Cronin, et al.Pageof 4